Regeneus - Several interested parties in Japan
Regeneus has revised expected timing of an osteoarthritis (OA) clinical development licence deal for Progenza in Japan to Q4 CY18 (vs Q218); it is...
Regeneus - Japan clinical licence deal expected near term
Regeneus is aiming to license Progenza for clinical development in Japan in the current quarter. A licence deal would trigger a US$5m milestone...
Preparing for a clinical licence deal in Japan
Regeneus is aiming to sign one or more clinical development licence deals for Progenza in the current financial year. It is well placed to achieve...
Positive STEP data and Japan patent grant
Regeneus announced that its Phase I STEP knee osteoarthritis (OA) trial met its primary safety endpoint at 12 months and produced promising signs...
Japan collaboration validates Progenza
Regeneus has entered into a US$16.5m collaboration with AGC Asahi Glass (AGC) for manufacture of Progenza for the Japanese market. Regeneus and AGC...
No more insights